JP5764792B2 - マクロライド免疫抑制剤を含む新規な医薬組成物 - Google Patents

マクロライド免疫抑制剤を含む新規な医薬組成物 Download PDF

Info

Publication number
JP5764792B2
JP5764792B2 JP2012532587A JP2012532587A JP5764792B2 JP 5764792 B2 JP5764792 B2 JP 5764792B2 JP 2012532587 A JP2012532587 A JP 2012532587A JP 2012532587 A JP2012532587 A JP 2012532587A JP 5764792 B2 JP5764792 B2 JP 5764792B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
tacrolimus
component
microemulsion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012532587A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507337A5 (cg-RX-API-DMAC10.html
JP2013507337A (ja
Inventor
アレグザンドラ ザビーネ ベーベル ゲーベル，
アレグザンドラ ザビーネ ベーベル ゲーベル，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skinomics GmbH
Original Assignee
Skinomics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skinomics GmbH filed Critical Skinomics GmbH
Publication of JP2013507337A publication Critical patent/JP2013507337A/ja
Publication of JP2013507337A5 publication Critical patent/JP2013507337A5/ja
Application granted granted Critical
Publication of JP5764792B2 publication Critical patent/JP5764792B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/4055—Concentrating samples by solubility techniques
    • G01N2001/4061—Solvent extraction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2012532587A 2009-10-08 2010-10-07 マクロライド免疫抑制剤を含む新規な医薬組成物 Active JP5764792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09012724.2 2009-10-08
EP09012724A EP2308468A1 (en) 2009-10-08 2009-10-08 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
PCT/EP2010/064965 WO2011042485A1 (en) 2009-10-08 2010-10-07 Novel pharmaceutical composition comprising a macrolide immunosuppressant drug

Publications (3)

Publication Number Publication Date
JP2013507337A JP2013507337A (ja) 2013-03-04
JP2013507337A5 JP2013507337A5 (cg-RX-API-DMAC10.html) 2013-11-07
JP5764792B2 true JP5764792B2 (ja) 2015-08-19

Family

ID=41435414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012532587A Active JP5764792B2 (ja) 2009-10-08 2010-10-07 マクロライド免疫抑制剤を含む新規な医薬組成物

Country Status (12)

Country Link
US (1) US8574562B2 (cg-RX-API-DMAC10.html)
EP (2) EP2308468A1 (cg-RX-API-DMAC10.html)
JP (1) JP5764792B2 (cg-RX-API-DMAC10.html)
KR (1) KR101790257B1 (cg-RX-API-DMAC10.html)
CN (1) CN102510752B (cg-RX-API-DMAC10.html)
AU (1) AU2010305404B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012007332B1 (cg-RX-API-DMAC10.html)
CA (1) CA2774720C (cg-RX-API-DMAC10.html)
ES (1) ES2552803T3 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN01559A (cg-RX-API-DMAC10.html)
MX (1) MX2012003800A (cg-RX-API-DMAC10.html)
WO (1) WO2011042485A1 (cg-RX-API-DMAC10.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
GEP20166459B (en) * 2011-06-23 2016-04-11 Santen Pharmaceutical Co Ltd Ophthalmic solution containing hyaluronic acid or salt thereof and propylene glycol
US10172789B2 (en) 2013-01-24 2019-01-08 Palvella Therapeutics Llc Compositions for transdermal delivery of mTOR inhibitors
CN103830178B (zh) * 2014-03-18 2017-01-11 深圳劲创生物技术有限公司 一种蒜氨酸微乳及其制备方法和应用
WO2017025588A1 (en) * 2015-08-11 2017-02-16 Eyesiu Medicines B.V. Pegylated lipid nanoparticle with bioactive lipophilic compound
CN109069418B (zh) 2016-04-04 2026-03-13 Mc2疗法有限公司 包含他克莫司的局部组合物
US20200323793A1 (en) * 2016-06-03 2020-10-15 Avexxin As Combination therapy comprising a polyunsaturated ketone and a calcineurin inhibitor
CN106074386A (zh) * 2016-08-31 2016-11-09 佛山市弘泰药物研发有限公司 一种依维莫司自微乳制剂及其制备方法
CA3037582A1 (en) 2016-09-21 2018-03-29 Avexxin As Pharmaceutical composition
WO2018129364A1 (en) 2017-01-06 2018-07-12 Palvella Therapeutics Llc Anhydrous compositions of mtor inhibitors and methods of use
US11766421B2 (en) 2017-09-25 2023-09-26 Surface Ophthalmics, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
WO2019233722A1 (en) 2018-06-08 2019-12-12 Almirall, S.A. Pharmaceutical composition comprising tacrolimus
EP3817743A4 (en) 2018-07-02 2022-07-06 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF MTOR INHIBITORS AND METHODS OF USE
JP2022516099A (ja) 2018-12-27 2022-02-24 サーフィス オフサルミクス，インコーポレイテッド 眼科用医薬組成物及び癌表面疾患の処置方法
EP4093396B1 (en) * 2020-01-22 2025-12-10 Bausch Health Ireland Limited Topical compositions comprising a macrolide immunosuppressant
TWI769745B (zh) * 2021-03-19 2022-07-01 國泰醫療財團法人國泰綜合醫院 醫藥組成物與製藥用途
US12440510B2 (en) 2021-05-10 2025-10-14 Surface Ophthalmics, Inc. Use of chondroitin sulfate for relieving ocular pain
CN117979951A (zh) 2021-05-10 2024-05-03 瑟菲斯眼科股份有限公司 一种用于缓解眼部疼痛的硫酸软骨素的用途
BE1030538B1 (nl) 2022-05-18 2023-12-19 Bogaert Gina Van Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan
KR102727647B1 (ko) * 2023-11-28 2024-11-08 장병모 칼시뉴린 억제제를 포함하는 피부질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH26083A (en) * 1987-11-09 1992-02-06 Sandoz Ltd 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof
GB2222770B (en) * 1988-09-16 1992-07-29 Sandoz Ltd Pharmaceutical compositions containing cyclosporins
CH686761A5 (de) * 1993-05-27 1996-06-28 Sandoz Ag Galenische Formulierungen.
GB2315216B (en) * 1993-10-05 1998-10-14 Ciba Geigy Ag Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin
DK0786986T3 (da) * 1994-10-26 2002-04-29 Novartis Ag Anvendelse af en umættet fedtalkohol
GB9723669D0 (en) * 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
EP1441696B1 (en) * 2001-11-01 2010-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method and composition for dry eye treatment
MXPA04005783A (es) * 2001-12-14 2004-09-13 Jagotec Ag Formulacion farmaceutica que comprende ciclosporina y uso de la misma.
AU2005263551B2 (en) * 2004-07-16 2009-04-09 Novartis Ag Use of a steroid for enhancement of skin permeability
CA2578176C (en) * 2004-11-09 2013-09-24 Novagali Pharma Sa Ophthalmic emulsions containing an immunosuppressive agent
KR100678829B1 (ko) * 2004-12-06 2007-02-05 한미약품 주식회사 타크로리무스의 경구용 마이크로에멀젼 조성물
WO2006123354A2 (en) * 2005-02-02 2006-11-23 Mega Lifesciences Pvt. Ltd. Oral pharmaceutical composition
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment

Also Published As

Publication number Publication date
CA2774720C (en) 2017-05-23
US8574562B2 (en) 2013-11-05
BR112012007332A2 (pt) 2016-10-04
KR20120093865A (ko) 2012-08-23
CN102510752B (zh) 2015-08-05
CN102510752A (zh) 2012-06-20
EP2485714A1 (en) 2012-08-15
EP2485714B1 (en) 2015-09-09
CA2774720A1 (en) 2011-04-14
IN2012DN01559A (cg-RX-API-DMAC10.html) 2015-06-05
MX2012003800A (es) 2012-06-28
AU2010305404B2 (en) 2015-04-02
AU2010305404A1 (en) 2012-03-08
ES2552803T3 (es) 2015-12-02
KR101790257B1 (ko) 2017-10-26
JP2013507337A (ja) 2013-03-04
US20120184511A1 (en) 2012-07-19
WO2011042485A1 (en) 2011-04-14
EP2308468A1 (en) 2011-04-13
BR112012007332B1 (pt) 2021-07-13

Similar Documents

Publication Publication Date Title
AU2010305404B2 (en) Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
JP2022180494A (ja) 局所製剤
CN114641297B (zh) 使用高克拉夫特温度阴离子表面活性剂治疗皮肤病症
JP2018123138A (ja) 半フッ化アルカンを基礎にした局所薬学的組成物
JP6030565B2 (ja) ミニエマルション、同ミニエマルションを形成するための方法および医薬品の製造における同ミニエマルションの使用
KR20160144377A (ko) 국소용 코르티코스테로이드 조성물
AU2021318201B2 (en) Topical formulation containing jak inhibitor and laureth-4
JP2022549216A (ja) 浸透促進剤を含有する脂質ベシクル組成物
CZ302649B6 (cs) Farmaceutická formulace zahrnující cyklosporin a její použití
MX2007011283A (es) Mejora de penetracion de macrolidos a traves de la piel humana.
CA3240662A1 (en) Stable formulations of shr0302
HK1167102A (en) Novel pharmaceutical composition comprising a macrolide immunosuppressant drug
CN108348456A (zh) 异维甲酸制剂及其用途和方法
US20080145434A1 (en) Compositions for the reversal and detoxification of anesthetics and other compounds and methods of their use
CN118660693A (zh) Shr0302的稳定制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20140620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140919

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140929

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141015

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150415

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20150512

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150512

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150529

R150 Certificate of patent or registration of utility model

Ref document number: 5764792

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250